Evaluate the effect of continuous subcutaneous apomorphine infusion (CSAI) on daily OFF time and Good ON time (ON without troublesome dyskinesia) via diaries in people with Parkinson disease (PD) and motor fluctuations.

The Phase 3 open-label InfusON study (NCT02339064) showed that, after 12 weeks of maintenance treatment with CSAI, patients’ daily OFF time decreased by a mean of -3.0 hours with a corresponding increase in Good ON time (+3.1 hours).

Of 99 enrolled patients, 65 had evaluable diaries at Baseline and Week 12. The infusion rate at Week 12 was median (range) 4 (1,7) mg/h. Waking-hour diary entries showed reduced OFF time for most patients (mean ± SD: -3.1 ± 3.16 h from Baseline: 6.6 ± 2.43), with some patients reporting no waking hour OFF time. The percent change from Baseline in the number of OFF periods was -40 ± 35.4%. The mean daily longest duration of uninterrupted Good ON time increased from 4.4 ± 2.73 h at Baseline to 9.6 ± 5.80 h at Week 12. Despite dyskinesia being commonly reported during titration, heat maps showed fewer patients reporting troublesome dyskinesia at Week 12 (n=6) than at Baseline (n=12).

CSAI therapy reduced patients’ daily number of OFF periods, reduced overall OFF time, and on average more than doubled longest duration uninterrupted Good ON time.